Detail page

Knowledge Web

Person

Ralf Gutzmer (1968-)

Arzt

Name	Ralf Gutzmer
Time	1968- (Date of birth and death)
Place	Hannover (Wirkungsort) Deutschland
Academic degree	Prof. Dr. med.
Profession	Arzt (characteristic profession) Hautarzt
Variant	R. Gutzmer
Related	Medizinische Hochschule Hannover Klinik für Dermatologie, Allergologie und Venerologie (Hannover)
Further information	Habil. Fach Dermatologie und Venerologie, Medizinische Hochschule Hannover, 2004
Record type	Person
GND-Identifier	113713371
Record ID	113713371
Involved in show all Preferences of physicians for treatment-related toxicity vs. recurrence in melanoma (GERMELATOX-A): the doctors’ perspective Influence of adjuvant therapies on organ‐specific recurrence of cutaneous melanoma: a multicenter study on 1383 patients of the prospective DeCOG registry ADOReg Influence of adjuvant therapies on organ‐specific recurrence of cutaneous melanoma: A multicenter study on 1383 patients of the prospective DeCOG registry ADOReg Preferences of physicians for treatment-related toxicity vs. recurrence in melanoma (GERMELATOX-A): the doctors’ perspective Preferences of German and Swiss melanoma patients for toxicities versus melanoma recurrence during adjuvant treatment (GERMELATOX-A-trial) Correlation of tumor PD-L1 expression in different tissue types and outcome of PD-1-based immunotherapy in metastatic melanoma – analysis of the DeCOG prospective multicenter cohort study ADOREG/TRIM Individuelle adjuvante Behandlung des malignen Melanoms : Patienten im Fokus der Immuntherapie Preferences of German and Swiss melanoma patients for toxicities versus melanoma recurrence during adjuvant treatment (GERMELATOX-A-trial) Long-term real-world experience with ipilimumab and non-ipilimumab therapies in advanced melanoma: the IMAGE study Vorgehen beim Basalzellkarzinom Vorgehen bei kutanem Plattenepithelkarzinom Immunhistochemische Untersuchungen des Expressionsprofils von PD-L1 im metastasierten malignen Melanom mit nachgewiesener BRAF-Mutation und Korrelation auf das Therapieansprechen mit einer zielgerichteten Therapie Long-term real-world experience with ipilimumab and non-ipilimumab therapies in advanced melanoma: the IMAGE study Patterns of care and follow-up care of patients with uveal melanoma in German-speaking countries: a multinational survey of the German Dermatologic Cooperative Oncology Group (DeCOG) Kutanes Plattenepithelkarzinom Combined immunotherapy with nivolumab and ipilimumab with and without local therapy in patients with melanoma brain metastasis: a DeCOG* study in 380 patients Nivolumab plus Ipilimumab, Nivolumab adjuvant : Diskussion zur Therapieentscheidung bei BRAF-mutierten Melanom Patienten Patterns of care and follow-up care of patients with uveal melanoma in German-speaking countries: a multinational survey of the German Dermatologic Cooperative Oncology Group (DeCOG) Kutanes Plattenepithelkarzinom Nivolumab plus Ipilimumab Kombination : etablierte Behandlungsoption des fortgeschrittenen Melanoms in der Erstlinientherapie für ein verbessertes Gesamtüberleben Kutanes Plattenepithelkarzinom A multicenter DeCOG study on predictors of vemurafenib therapy outcome in melanoma: pretreatment impacts survival Das maligne Melanom : Vorsorgen, Erkennen, Behandeln Konservative Therapie des Basalzellkarzinoms sowie des Gorlin-Goltz-Syndroms Konservative Therapie des Basalzellkarzinoms sowie des Gorlin-Goltz-Syndroms Treatment of unresectable stage IV metastatic melanoma with aviscumine after anti-neoplastic treatment failure: a phase II, multi-centre study Kutane Nebenwirkungen der medikamentösen Tumortherapie mit BRAF- und MEK-Inhibitoren Konservative Therapie des Basalzellkarzinoms sowie des Gorlin-Goltz-Syndroms The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab Network Beiträge zur Modulation der Funktion dendritischer Zellen Charakterisierung des sekundären myelodysplastischen Syndromes unter besonderer Berücksichtigung der Histopathologie

Please note

The beta version does not yet contain all functions and information of the DNB portal catalogue. If you are missing information or want to order a medium, please visit the page in the DNB portal catalogue via the following link:

Katalog der Deutschen Nationalbibliothek

Ralf Gutzmer (1968-)

Preferences of physicians for treatment-related toxicity vs. recurrence in melanoma (GERMELATOX-A): the doctors’ perspective

Influence of adjuvant therapies on organ‐specific recurrence of cutaneous melanoma: a multicenter study on 1383 patients of the prospective DeCOG registry ADOReg

Influence of adjuvant therapies on organ‐specific recurrence of cutaneous melanoma: A multicenter study on 1383 patients of the prospective DeCOG registry ADOReg

Preferences of physicians for treatment-related toxicity vs. recurrence in melanoma (GERMELATOX-A): the doctors’ perspective

Preferences of German and Swiss melanoma patients for toxicities versus melanoma recurrence during adjuvant treatment (GERMELATOX-A-trial)

Correlation of tumor PD-L1 expression in different tissue types and outcome of PD-1-based immunotherapy in metastatic melanoma – analysis of the DeCOG prospective multicenter cohort study ADOREG/TRIM

Individuelle adjuvante Behandlung des malignen Melanoms : Patienten im Fokus der Immuntherapie

Preferences of German and Swiss melanoma patients for toxicities versus melanoma recurrence during adjuvant treatment (GERMELATOX-A-trial)

Long-term real-world experience with ipilimumab and non-ipilimumab therapies in advanced melanoma: the IMAGE study

Vorgehen beim Basalzellkarzinom

Vorgehen bei kutanem Plattenepithelkarzinom

Immunhistochemische Untersuchungen des Expressionsprofils von PD-L1 im metastasierten malignen Melanom mit nachgewiesener BRAF-Mutation und Korrelation auf das Therapieansprechen mit einer zielgerichteten Therapie

Long-term real-world experience with ipilimumab and non-ipilimumab therapies in advanced melanoma: the IMAGE study

Patterns of care and follow-up care of patients with uveal melanoma in German-speaking countries: a multinational survey of the German Dermatologic Cooperative Oncology Group (DeCOG)

Kutanes Plattenepithelkarzinom

Combined immunotherapy with nivolumab and ipilimumab with and without local therapy in patients with melanoma brain metastasis: a DeCOG* study in 380 patients

Nivolumab plus Ipilimumab, Nivolumab adjuvant : Diskussion zur Therapieentscheidung bei BRAF-mutierten Melanom Patienten

Patterns of care and follow-up care of patients with uveal melanoma in German-speaking countries: a multinational survey of the German Dermatologic Cooperative Oncology Group (DeCOG)

Kutanes Plattenepithelkarzinom

Nivolumab plus Ipilimumab Kombination : etablierte Behandlungsoption des fortgeschrittenen Melanoms in der Erstlinientherapie für ein verbessertes Gesamtüberleben

Kutanes Plattenepithelkarzinom

A multicenter DeCOG study on predictors of vemurafenib therapy outcome in melanoma: pretreatment impacts survival

Das maligne Melanom : Vorsorgen, Erkennen, Behandeln

Konservative Therapie des Basalzellkarzinoms sowie des Gorlin-Goltz-Syndroms

Konservative Therapie des Basalzellkarzinoms sowie des Gorlin-Goltz-Syndroms

Treatment of unresectable stage IV metastatic melanoma with aviscumine after anti-neoplastic treatment failure: a phase II, multi-centre study

Kutane Nebenwirkungen der medikamentösen Tumortherapie mit BRAF- und MEK-Inhibitoren

Konservative Therapie des Basalzellkarzinoms sowie des Gorlin-Goltz-Syndroms

The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network

The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab Network

Beiträge zur Modulation der Funktion dendritischer Zellen

Charakterisierung des sekundären myelodysplastischen Syndromes unter besonderer Berücksichtigung der Histopathologie